Nicholas Pena

The paper tests a G2019S selective LRRK2 inhibitor, EB-42168, showing it reduces mtDNA damage in G2019S models and patient cells better than a non-selective inhibitor.

The paper identifies mtDNA damage as a blood-based biomarker for Parkinson's disease, showing increased levels in early-stage patients and mutation carriers, suggesting its potential for patient stratification in clinical trials.